Skip to main content

Trastuzumab Deruxtecan Meets ORR End Point in HER2-expressing Advanced Solid Tumors

*March 2023*

The antibody-drug conjugate (ADC) fam-trastuzumab deruxtecan-nxki (Enhertu) met the prespecified target for objective response rate (ORR) and demonstrated durable responses in heavily pretreated patients with HER2-expressing advanced solid tumors in the phase 2 DESTINY-PanTumor02 trial (NCT04482309).1

The trial included previously treated patients with locally advanced, unresectable, or metastatic solid tumors, such as biliary tract, bladder, cervical, endometrial, ovarian, pancreatic, and rare cancers, who were not eligible for curative therapy. Read more.